Presentation is loading. Please wait.

Presentation is loading. Please wait.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Published byMalcolm Janey Modified over 10 years ago

Similar presentations

Presentation on theme: "Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,"— Presentation transcript:

1 Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka, Juan Du, Richard F. Schlenk, Verena I. Gaidzik, Lars Bullinger, Andrea Corbacioglu, Daniela Späth, Sabine Kayser, Brigitte Schlegelberger, Jürgen Krauter, Arnold Ganser, Claus-Henning Köhne, Gerhard Held, Marie von Lilienfeld- Toal, Heinz Kirchen, Mathias Rummel, Katharina Götze, Heinz-August Horst, Mark Ringhoffer, Michael Lübbert, Mohammed Wattad, Helmut R. Salih, Andrea Kündgen, Hartmut Döhner, and Konstanze Döhner Blood Volume 121(1):170-177 January 3, 2013 ©2013 by American Society of Hematology

2 Pie chart illustrating the genetic heterogeneity and coexistence of the distinct secondary genetic abnormalities in AML with inv (16). Paschka P et al. Blood 2013;121:170-177 ©2013 by American Society of Hematology

3 Impact of trisomy 22 on RFS and OS. (A) RFS. (B) OS. Paschka P et al. Blood 2013;121:170-177 ©2013 by American Society of Hematology

4 Impact of trisomy 8 on OS. Paschka P et al. Blood 2013;121:170-177 ©2013 by American Society of Hematology

5 Impact of KIT mutations on RFS. Paschka P et al. Blood 2013;121:170-177 ©2013 by American Society of Hematology

6 Impact of FLT3 mutations on OS. Paschka P et al. Blood 2013;121:170-177 ©2013 by American Society of Hematology

Download ppt "Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,"

Similar presentations

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13):4793-4807 December 15, 2008 ©2008 by American Society of Hematology.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.
Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with.

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with.
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Neonatal GATA1 mutant clones under the radar

Neonatal GATA1 mutant clones under the radar
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,
Defects in DBA: more than meets the eye

Defects in DBA: more than meets the eye
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Similar presentations

Ads by Google